CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS)
MASH
CHOLESTASIS
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Embassy of Education CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Webcasts Abstract Library Committee Members
 
HBV-Single Disease Content  
Featured Article

Webcasts
HBV/HDV-ACT Connect (ADVANCING CURATIVE TREATMENTS)   Educational Webcast
Hepatitis B and D Infection   Educational Webcast
HBV/HDV Hot Topics & Virtual Roundtable   Educational Webcast
HBV, HCV, and HDV   Educational Webcast
 
 
Slide Library
   Released: 2023
Webcast
Stopping All Therapy in HBV Clinical Trials: What Should Be the Criteria for Discontinuation
23 slides
 
 
   Released: 2023
Webcast
New Insights Into The Biology Of HDV: Implications For Drug Development
42 slides
 
 
   Released: 2023
Webcast
HBV Overview of the Last 3 Years For Drug Development: Phase 2 Trials
43 slides
 
 
   Released: 2023
Webcast
Emerging Therapies for HBV in the Next Three Years (Pre-clinical to Phase 1)
31 slides
 
 
   Released: 2023
Webcast
What Are the Most Promising Immunomodulatory Therapies for HBV Infection?
29 slides
 
 
   Released: 2023
Webcast
Emerging Concepts and Data CpAMS Third and Fourth Generation
33 slides
 
 
   Released: 2023
Webcast
Does the New Data on HBV DNA Integration and HBsAg Production Effect the Design and Definition of Treatment Endpoints of Phase II and Phase III Studies?
20 slides
 
 
   Released: 2023
Webcast
Is there a real difference between ETV and TDF/TAF in relapse and HCC?
27 slides
 
 
   Released: 2023
Webcast
How Do We Fit FNA and Liver Biopsy Into HBV Drug Development and Design? Should All Studies Have FNA Subset and Examine Intrahepatic Immune Activity? CccDNA? Integrants?
19 slides
 
 
   Released: 2023
Webcast
Should All Patients With HDV Be Treated?
22 slides
 
 
   Released: 2023
Webcast
HDV Update: Review of the Last 3 Years
18 slides
 
 
   Released: 2023
Webcast
Hepatitis Delta: How Should Bulevirtide Be Used in Clinical Practice
27 slides
 
 
   Released: 2023
Webcast
What Other Therapies Are Being Developed for HDV Infection? NAPS, Lambda, and Lonafarnib
36 slides
 
 
   Released: 2023
Webcast
What Is the Role of Interferon Therapy in HDV?
30 slides
 
 
   Released: 2021
Webcast
HBV Alliance: Expert Recommendations on Managing Patients with Chronic Hepatitis B
56 slides
 
 
   Released: 2021
Webcast
Acute HBV
17 slides
 
 
   Released: 2021
Webcast
Chemotherapy/Reactivation
26 slides
 
 
   Released: 2021
Webcast
Current Management of Chronic Hepatitis B
30 slides
 
 
   Released: 2021
Webcast
Epidemiology of HBV
34 slides
 
 
   Released: 2021
Webcast
Evaluation of the Patient With Chronic HBV
26 slides
 
 
   Released: 2021
Webcast
Everything Old Is New Again!
41 slides
 
 
   Released: 2021
Webcast
Extrahepatic Manifestations of Hepatitis B
34 slides
 
 
   Released: 2021
Webcast
HBsAg Quant HBV Genotyping HBV RNA Quant Where We Are in 2020
41 slides
 
 
   Released: 2021
Webcast
HBV & Hepatitis D (Delta)
26 slides
 
 
   Released: 2021
Webcast
HBV and Liver Cancer
34 slides
 
 
   Released: 2021
Webcast
HBV and NAFLD
35 slides
 
 
   Released: 2021
Webcast
HBV Coinfection With HCV or HIV
35 slides
 
 
   Released: 2021
Webcast
HBV: New Therapies & Clinical Trials
37 slides
 
 
   Released: 2021
Webcast
Hepatitis B Screening: CDC, AASLD, USPSTF
24 slides
 
 
   Released: 2021
Webcast
Hepatitis B: Treatment Endpoints
27 slides
 
 
   Released: 2021
Webcast
Hepatitis B: Update on Treatment Guidelines
27 slides
 
 
   Released: 2021
Webcast
How to Diagnose Hepatitis B
25 slides
 
 
   Released: 2021
Webcast
Immunization for HBV
31 slides
 
 
   Released: 2021
Webcast
Management of HBV: New Data
26 slides
 
 
   Released: 2021
Webcast
Natural History of HBV
39 slides
 
 
   Released: 2021
Webcast
Treatment of Hepatitis B: Controversies 2020
63 slides
 
 
   Released: 2021
Webcast
Update on Hepatitis B
54 slides
 
 
   Released: 2021
Webcast
WHO Hepatitis Elimination Targets
46 slides
 
 
   
     
 
 
 
Abstract Library
1.Infection, inflammation and hepatic encephalopathy from a clinical perspective
 

Metab Brain Dis. 2024 Aug 30. doi: 10.1007/s11011-024-01402-y.Online ahead of print.

Yevedzo Ntuli 1 2, Debbie L Shawcross 3 4
 
2.Serum Ammonia Levels Do Not Correlate With Overt Hepatic Encephalopathy Severity in Hospitalized Patients With Cirrhosis
 

ClinGastroenterolHepatol. 2024Sep;22(9):19501952.e1. doi:10.1016/j.cgh.2024.02.015.Epub2024 Feb 28.

Jasmohan S Bajaj 1, Nikolaos T Pyrsopoulos 2, Robert S Rahimi 3, Zeev Heimanson 4, Christopher Allen 4, Don C Rockey 5
 
3.Advances in the management of complications from cirrhosis
 

Gastroenterol Rep (Oxf). 2024 Aug 5:12:goae072. doi: 10.1093/gastro/goae072.eCollection 2024.

Jasleen Singh 1 2, Mark Ebaid 1, Sammy Saab 1 2
 
4.Retrospective Database Analysis of Liver-Related Clinical Events in Adult and Pediatric Patients with Alpha-1 Antitrypsin Deficiency in the United States
 

Hepat Med. 2024 Jul 24:16:55-64. doi: 10.2147/HMER.S469769. eCollection 2024.

May Hagiwara 1, Victoria Divino 2, Swapna Munnangi 2, Mark Delegge 2, Suna Park 1, Ed G Marins 3, Kaili Ren 4, Charlie Strange 5
 
5.Medication burden and anticholinergic use are associated with overt HE in individuals with cirrhosis
 

Hepatol Commun. 2024 Jul 22;8(8):e0460. doi: 10.1097/HC9.0000000000000460.eCollection 2024 Aug 1.

Jonathan A Montrose 1, Archita Desai 2, Lauren Nephew 2, Kavish R Patidar 2, Marwan S Ghabril 2, Noll L Campbell 3, Naga Chalasani 2, Yingjie Qiu 4, Matthew E Hays 4, Eric S Orman 2
 
6.The social and psychological impact of hepatic encephalopathy
 

Metab Brain Dis. 2024 Jul 16. doi: 10.1007/s11011-024-01384-x.Online ahead of print.

Michael Sørensen 1 2, Mette Munk Lauridsen 3, Sara Montagnese 4 5

 
 
7.Association of Acetaminophen (Paracetamol) Use with Severity and Outcomes in Patients with Viral Hepatitis-Associated Acute Liver Failure
 

Am J Gastroenterol. 2024 Jul 12. doi: 10.14309/ajg.0000000000002941. Online ahead of print.

William M Lee 1, Carson Barnard 1, Jody A Rule 1, Babak J Orandi 2, Laura P James 3, R Todd Stravitz 4, Valerie Durkalski 5, Robert J Fontana 6; Acute Liver Failure Study Group
 
8.Advances in the management of complications from cirrhosis
 

Gastroenterol Rep (Oxf). 2024 Aug 5:12:goae072. doi: 10.1093/gastro/goae072.eCollection 2024.

Jasleen Singh 1 2, Mark Ebaid 1, Sammy Saab 1 2
 
9.Retrospective Database Analysis of Liver-Related Clinical Events in Adult and Pediatric Patients with Alpha-1 Antitrypsin Deficiency in the United States
 

Hepat Med. 2024 Jul 24:16:55-64. doi: 10.2147/HMER.S469769. eCollection 2024.

 

May Hagiwara 1, Victoria Divino 2, Swapna Munnangi 2, Mark Delegge 2, Suna Park 1, Ed G Marins 3, Kaili Ren 4, Charlie Strange 5
 
10.Medication burden and anticholinergic use are associated with overt HE in individuals with cirrhosis
 

Hepatol Commun. 2024 Jul 22;8(8):e0460. doi: 10.1097/HC9.0000000000000460.eCollection 2024 Aug 1.

 

Jonathan A Montrose 1, Archita Desai 2, Lauren Nephew 2, Kavish R Patidar 2, Marwan S Ghabril 2, Noll L Campbell 3, Naga Chalasani 2, Yingjie Qiu 4, Matthew E Hays 4, Eric S Orman 2
 
11.The social and psychological impact of hepatic encephalopathy
 

Metab Brain Dis. 2024 Jul 16. doi: 10.1007/s11011-024-01384-x.Online ahead of print.

 

Michael Sørensen 1 2, Mette Munk Lauridsen 3, Sara Montagnese 4 5
 
12.Association of Acetaminophen (Paracetamol) Use with Severity and Outcomes in Patients with Viral Hepatitis-Associated Acute Liver Failure
 

Am J Gastroenterol. 2024 Jul 12. doi: 10.14309/ajg.0000000000002941. Online ahead of print.

 

William M Lee 1, Carson Barnard 1, Jody A Rule 1, Babak J Orandi 2, Laura P James 3, R Todd Stravitz 4, Valerie Durkalski 5, Robert J Fontana 6; Acute Liver Failure Study Group
 
13.A Possible Reversible Cause of Cognitive Impairment: Undiagnosed Cirrhosis and Potential Hepatic Encephalopathy in Patients with Dementia
 

Am J Med. 2024 Jun 26:S0002-9343(24)00398-X. doi: 10.1016/j.amjmed.2024.06.014.Online ahead of print.

 

Scott Silvey 1, Richard K Sterling 2, Evan French 3, Michael Godschalk 4, Angela Gentili 4, Nilang Patel 5, Jasmohan S Bajaj 6
 
14.Hepatic encephalopathy: a neurologist's perspective
 

Pract Neurol. 2024 May 29;24(3):200-206. doi: 10.1136/pn-2023-003802.

 

Edward Needham 1 2, Gwilym Webb 3
 
15.Key Insights and Clinical Pearls in the Identification and Management of Cirrhosis and Its Complications
 

Am J Med. 2024 May 22:S0002-9343(24)00326-7.doi: 10.1016/j.amjmed.2024.05.015. Online ahead of print.

 

Steven L Flamm 1
 
16.Differential Effects of Ascites and Hepatic Encephalopathy on Waitlist Mortality in Liver Transplantation by MELD 3.0
 

Transplant Direct. 2024 May 15;10(6):e1625. doi:10.1097/TXD.0000000000001625.eCollection 2024 Jun.

 

Brian T Lee 1 2, Nathan T Chen 1, Tse-Ling Fong 1 2, Jennifer L Dodge 2 3
 
17.The conflicts of Ray Adams and Joe Foley with Abe Baker: The neurology and neuropathology of liver failure (1949-1963) and the founding of the American Academy of Neurology (1948)
 

J Hist Neurosci. 2024 Apr 15:1-13.doi: 10.1080/0964704X.2024.2336463.Online ahead of print.

Douglas J Lanska 1
 
18.History of depression is associated with higher prevalence of hepatic encephalopathy in patients with advanced liver disease
 

Am J Med. 2024 May 8:S0002-9343(24)00275-4. doi: 10.1016/j.amjmed.2024.04.036.Online ahead of print.

 

Katherine M Cooper 1, Alessandro Colletta 1, Brian Osorio 1, Emilee Herringshaw 1, Arslan Talat 2, Deepika Devuni 3
 
19.Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence
 

Hepatol Commun. 2024 May 10;8(6):e0436.doi: 10.1097/HC9.0000000000000436. eCollection 2024 Jun 1.

 

Arun J Sanyal 1, Kris V Kowdley 2, Nancy S Reau 3, Nikolaos T Pyrsopoulos 4, Christopher Allen 5, Zeev Heimanson 5, Jasmohan S Bajaj 1 6
 
20.Interventional Radiology Management of Hepatic Encephalopathy
 

Clin Liver Dis. 2024 May;28(2):317-329. doi: 10.1016/j.cld.2024.01.008.Epub 2024 Feb 10.

 

Edward Wolfgang Lee 1, Justine J Liang 2, Griffin P McNamara 3
 
21.Pathophysiology of Hepatic Encephalopathy: A Framework for Clinicians
 

Clin Liver Dis. 2024 May;28(2):209-224. doi: 10.1016/j.cld.2024.01.002.Epub 2024 Feb 20.

 

Alexander Chen 1, Christopher Tait 2, Carlos Minacapelli 3, Vinod Rustgi 4
 
22.The Health Care Burden of Hepatic Encephalopathy
 

Clin Liver Dis. 2024 May;28(2):265-272. doi: 10.1016/j.cld.2024.01.009.Epub 2024 Feb 12.

 

Kevin B Harris 1, Humberto C Gonzalez 2, Stuart C Gordon 3
 
23.Preventing Readmissions of Hepatic Encephalopathy: Strategies in the Acute Inpatient, Immediate Postdischarge, and Longitudinal Outpatient Setting
 

Clin Liver Dis. 2024 May;28(2):359-367. doi: 10.1016/j.cld.2024.01.010.Epub 2024 Feb 12.

 

Emily Lin 1, Devika Gandhi 2, Michael Volk 3
 
24.Preventing Readmissions for Hepatic Encephalopathy
 

Clin Liver Dis. 2024 May;28(2):345-358. doi: 10.1016/j.cld.2024.01.001.Epub 2024 Jan 30.

 

Salima S Makhani 1, Susan Lee 2, David Bernstein 3
 
25.Social Impact of Hepatic Encephalopathy
 

Clin Liver Dis. 2024 May;28(2):273-285. doi: 10.1016/j.cld.2024.01.011.Epub 2024 Feb 12.

 

Akshay Shetty 1, Elena G Saab 2, Gina Choi 3
 
View More
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

MASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2024 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2024 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.